Skip to content
Screener

Gyre Therapeutics, Inc. GYRE Q4 2025 Annual earnings

Reported March 12, 2026 · Before market open

Revenue$37.2MBeat by $1.8M
EPS$0.04Miss by $0.02
Revenue estimate$35.4M
EPS estimate$0.06

Next report

Nov 6, 2026 (in 2 months)
Revenue estimate$28.4M
EPS estimate-$0.15

Financials

Q4 2025

Income statement

See full
Revenue$37.2M+33.4%
Gross profit$35.5M+32.8%
Operating income$118.0K-82.3%
Net income$763.0K—
EPS (diluted)$0.02—

Balance sheet

See full
Cash & equivalents$49.2M+316%
Total debt$939.0K-41.2%
Total equity$62.5M-1.3%
Total assets$219.8M+75.2%

Cash flow

See full
CapEx$144.0K—
Free cash flow-$5.8M-114%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$680.11M-34.5%
Enterprise value$631.86M-38.5%
P/E135.3×+50.1×
P/S5.7×-4.1×

Profitability

See full
Gross margin95.5%-0.9pp
Operating margin5.9%-9.4pp
Net margin4.2%-7.3pp
FCF margin-0.2%—

Returns & leverage

See full
Return on equity8%—
Debt / equity0×0.0×
Current ratio6.3×+3.0×

Segments

By product

See full
Contiva$2.5M—
Etorel$1.5M—
Other Product$72.9K-52.3%

By segment

See full
Gyre Pharmaceuticals$37.2M+33.4%

FAQ

When did Gyre Therapeutics, Inc. report Q4 2025 earnings?
Gyre Therapeutics, Inc. (GYRE) reported Q4 2025 earnings on March 12, 2026 before market open.
What were Gyre Therapeutics, Inc.'s Q4 2025 revenue and EPS?
Gyre Therapeutics, Inc. reported revenue of $37.2M and eps of $0.04 for Q4 2025.
Did Gyre Therapeutics, Inc. beat estimates in Q4 2025?
Revenue beat the consensus estimate of $35.4M by $1.8M. EPS missed the consensus estimate of $0.06 by $0.02.
How did Gyre Therapeutics, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 33.4% from $27.9M a year earlier and eps grew 300.0% from $0.01.
Where can I find Gyre Therapeutics, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-102700) and the 10-K periodic report (0001193125-26-106251) directly on SEC EDGAR. The filing index links above go to sec.gov.